ESR1 and neoplasm: For instance, Composite Risk model have been proved to predict long‐term outcomes for patients receiving adjuvant treatment, whereas the scoring system incorporating pretreatment clinical stage and post‐treatment pathologic stage as well as estrogen receptor status and tumor grade (CPS+EG system) showed predictive values in neoadjuvant settings.8, 9